{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:36:15Z","timestamp":1759941375272,"version":"3.41.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the use of tenofovir alafenamide (TAF), a new prodrug of tenofovir, was safe and efficacious in clinical trials, real-world data from multimorbid individuals are scarce. Among 10 persons living with HIV with previous tenofovir disoproxil fumarate\u2013induced nephrotoxicity, renal function remained stable, and proteinuria decreased in several patients after the switch to TAF.<\/jats:p>","DOI":"10.1093\/ofid\/ofy275","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T05:24:59Z","timestamp":1543469099000},"source":"Crossref","is-referenced-by-count":7,"title":["Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity"],"prefix":"10.1093","volume":"5","author":[{"given":"Laura N","family":"Walti","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Steinr\u00fccken","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"2020081011063834300_CIT0001","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2020081011063834300_CIT0002","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020081011063834300_CIT0003","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"2020081011063834300_CIT0004","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","article-title":"Fanconi syndrome and renal failure induced by tenofovir: a first case report","volume":"40","author":"Verhelst","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2020081011063834300_CIT0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Mulligan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081011063834300_CIT0006","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000001069","article-title":"Efficacy and safety of switching to a single-tablet regimen of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) in HIV-1\/hepatitis B coinfected adults","author":"Gallant","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081011063834300_CIT0007","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"2020081011063834300_CIT0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020081011063834300_CIT0009","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081011063834300_CIT0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"2020081011063834300_CIT0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/COH.0000000000000379","article-title":"Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide","volume":"12","author":"Gotham","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2020081011063834300_CIT0012","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1089\/aid.2016.0180","article-title":"Short communication: resolution of tenofovir disoproxil fumarate induced Fanconi syndrome with switch to tenofovir alafenamide fumarate in a HIV-1 and hepatitis B coinfected patient","volume":"33","author":"Karris","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081011063834300_CIT0013","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1097\/QAD.0000000000001623","article-title":"Successful treatment with tenofovir alafenamide of a HIV\/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis","volume":"31","author":"Tartaglia","year":"2017","journal-title":"AIDS"},{"key":"2020081011063834300_CIT0014","article-title":"Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance","author":"Grossi","year":"2017","journal-title":"J Hepatol"},{"key":"2020081011063834300_CIT0015","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","article-title":"Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus","volume":"139","author":"de Vries-Sluijs","year":"2010","journal-title":"Gastroenterology"},{"key":"2020081011063834300_CIT0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.27182","article-title":"Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications","volume":"60","author":"Boyd","year":"2014","journal-title":"Hepatology"},{"key":"2020081011063834300_CIT0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/ckj\/sfv041","article-title":"Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series","volume":"8","author":"Waheed","year":"2015","journal-title":"Clin Kidney J"},{"key":"2020081011063834300_CIT0018","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/QAD.0000000000001667","article-title":"Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued","volume":"32","author":"Nishijima","year":"2018","journal-title":"AIDS"},{"key":"2020081011063834300_CIT0019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/QAI.0000000000000986","article-title":"Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients","volume":"72","author":"Casado","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081011063834300_CIT0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","article-title":"Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study","volume":"74","author":"Post","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"author":"Podzamczer","key":"2020081011063834300_CIT0021","article-title":"Adults with renal impairment switching from tenofovir disoproxil fumarate to tenofovir alafenamide have improved renal and bone safety through 144 weeks, presentation MOPEB0288"},{"key":"2020081011063834300_CIT0022","doi-asserted-by":"crossref","first-page":"e8046","DOI":"10.1097\/MD.0000000000008046","article-title":"Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report","volume":"96","author":"Novick","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2020081011063834300_CIT0023","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy189","article-title":"Acute kidney injury in a patient on tenofovir alafenamide fumarate after initiation of treatment for hepatitis C virus infection","volume":"5","author":"Serota","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/11\/ofy275\/33629683\/ofy275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/11\/ofy275\/33629683\/ofy275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T03:33:46Z","timestamp":1662521626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy275\/5144205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy275","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,10,24]]},"article-number":"ofy275"}}